122 related articles for article (PubMed ID: 11287119)
21. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.
Gupta N; Delrow J; Drawid A; Sengupta AM; Fan G; Gélinas C
Cancer Res; 2008 Feb; 68(3):808-14. PubMed ID: 18245482
[TBL] [Abstract][Full Text] [Related]
22. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
Nehyba J; Hrdlicková R; Bose HR
Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
[TBL] [Abstract][Full Text] [Related]
23. Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.
Nehyba J; Hrdlicková R; Humphries EH
J Virol; 1994 Apr; 68(4):2039-50. PubMed ID: 8138989
[TBL] [Abstract][Full Text] [Related]
24. v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.
Hrdlicková R; Nehyba J; Humphries EH
J Virol; 1994 Jan; 68(1):308-19. PubMed ID: 8254742
[TBL] [Abstract][Full Text] [Related]
25. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
[TBL] [Abstract][Full Text] [Related]
26. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
Carrasco D; Rizzo CA; Dorfman K; Bravo R
EMBO J; 1996 Jul; 15(14):3640-50. PubMed ID: 8670867
[TBL] [Abstract][Full Text] [Related]
27. Temperature-sensitive transforming mutants of the v-rel oncogene.
White DW; Gilmore TD
J Virol; 1993 Nov; 67(11):6876-81. PubMed ID: 8411392
[TBL] [Abstract][Full Text] [Related]
28. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death.
Zong WX; Farrell M; Bash J; Gélinas C
Oncogene; 1997 Aug; 15(8):971-80. PubMed ID: 9285692
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
Bhat GV; Temin HM
Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
[TBL] [Abstract][Full Text] [Related]
30. Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.
Kralova J; Schatzle JD; Bargmann W; Bose HR
J Virol; 1994 Apr; 68(4):2073-83. PubMed ID: 8138992
[TBL] [Abstract][Full Text] [Related]
31. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines.
Gilmore TD; Jean-Jacques J; Richards R; Cormier C; Kim J; Kalaitzidis D
Virology; 2003 Nov; 316(1):9-16. PubMed ID: 14599786
[TBL] [Abstract][Full Text] [Related]
32. The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein.
Kumar S; Rabson AB; Gélinas C
Mol Cell Biol; 1992 Jul; 12(7):3094-106. PubMed ID: 1620118
[TBL] [Abstract][Full Text] [Related]
33. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site.
Capobianco AJ; Gilmore TD
Oncogene; 1991 Dec; 6(12):2203-10. PubMed ID: 1766669
[TBL] [Abstract][Full Text] [Related]
34. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.
You M; Ku PT; Hrdlicková R; Bose HR
Mol Cell Biol; 1997 Dec; 17(12):7328-41. PubMed ID: 9372964
[TBL] [Abstract][Full Text] [Related]
35. Mutations within a conserved protein kinase A recognition sequence confer temperature-sensitive and partially defective activities onto mouse c-Rel.
Gapuzan ME; Pitoc GA; Gilmore TD
Biochem Biophys Res Commun; 2003 Jul; 307(1):92-9. PubMed ID: 12849986
[TBL] [Abstract][Full Text] [Related]
36. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
Gélinas C; Temin HM
Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247
[TBL] [Abstract][Full Text] [Related]
37. Methods for assessing the in vitro transforming activity of NF-κB transcription factor c-Rel and related proteins.
Gilmore TD; Gélinas C
Methods Mol Biol; 2015; 1280():427-46. PubMed ID: 25736765
[TBL] [Abstract][Full Text] [Related]
38. A mutant v-rel with increased ability to transform B lymphocytes.
Romero P; Humphries EH
J Virol; 1995 Jan; 69(1):301-7. PubMed ID: 7983722
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro.
Barkett M; Xue D; Horvitz HR; Gilmore TD
J Biol Chem; 1997 Nov; 272(47):29419-22. PubMed ID: 9367996
[TBL] [Abstract][Full Text] [Related]
40. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Sarkar S; Gilmore TD
Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
